EZH2 and metastatic neoplasm: In breast cancer patients, progression to advanced and metastatic disease is accompanied by decreased miR-101 and reciprocal EZH2 upregulation, and functional studies show that restoring miR-101 restrains invasion by lowering EZH2 and its repressive mark [143,144].